Related Experiment Video
Updated: May 26, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle?
Robert Ralston1, Ira Jacobson, Margaret Scull
1Laboratory of Virology and Infectious Disease and Center for the Study of Hepatitis C, The Rockefeller University, New York, NY, USA. ralstonr@missouri.edu
Insights
New hepatitis C treatments effectively lower viral load, but some patients relapse. This suggests the hepatitis C virus (HCV) may persist in forms resistant to current antiviral therapies.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Direct-acting antivirals (DAAs) combined with pegylated interferon and ribavirin (PEG-IFN/RBV) have improved chronic hepatitis C treatment outcomes.
- Sustained virologic response is common, but a subset of patients relapse after treatment completion despite undetectable viral loads during therapy.
Purpose of the Study:
- To investigate the molecular mechanisms of hepatitis C virus (HCV) persistence.
- To understand the clinical virology of relapse in patients treated with DAAs and PEG-IFN/RBV.
Main Methods:
- Review of HCV molecular biology and replication strategies.
- Analysis of clinical data on patient relapse following antiviral therapy.
Main Results:
- HCV may persist in forms resistant to eradication by current antiviral regimens.
- Relapse suggests the virus can survive extensive antiviral pressure and re-emerge post-treatment.
Conclusions:
- The persistence of HCV in refractory forms presents a challenge to achieving a complete cure.
- Further research into viral survival mechanisms is crucial for developing strategies to prevent relapse.
Abstract:
New treatments for chronic hepatitis C combining direct-acting antivirals (DAAs) with pegylated interferon and ribavirin (PEG-IFN/RBV) have dramatically increased the number of patients whose viral load declines to undetectable levels early in treatment. Most go on to achieve a sustained virologic response, but some patients who maintain undetectable levels of virus throughout treatment later relapse during follow-up. These data suggest that hepatitis C virus (HCV) genomes may persist in form(s) that are refractory to eradication by DAAs and PEG-IFN/RBV. Here we examine the molecular biology of HCV replication and review the clinical virology of relapse for clues as to how the virus might survive months of antiviral therapy to later reappear when treatment is withdrawn.
Related Concept Videos
Retrovirus Life Cycles
Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe and...
Hepatitis
Psychological and Sociocultural Causes of Schizophrenia
Viruses with RNA Genomes
Cirrhosis II: Pathophysiology

